Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 5 min ago
Peer-reviewedCC BY 4.0JAMA Network Open

Long-Acting Lenacapavir and Cabotegravir and Viral Suppression Among People With HIV

  • Nathanael L. Gistand1
  • Ishaan C. Mishra1
  • Kyle Hunter1
  • Megan J. Heise1
  • Chesa Cox1
  • Janet Grochowski1
  • Francis Mayorga-Munoz1
  • Jon Oskarsson1
  • Mary Shiels1
  • Matthew A. Spinelli1
  • Monica Gandhi1
  1. 1Division of HIV, ID, and Global Medicine, University of California, San Francisco
Open at sourceDOICite

Abstract

This case series examines viral suppression outcomes among patients with HIV with prior adherence challenges, treatment experience, and resistance initiating lenacapavir and cabotegravir.

Related

  1. Virological outcomes, resistance profile and viral evolution of lenacapavir-based regimens in heavily treatment-experienced people: data from the PRESTIGIO Registry.
    Maria Mercedes Santoro, Daniele Spalletta, Vincenzo Spagnuolo +17
    The Journal of antimicrobial chemotherapyPeer-reviewedCC BYFull textInfectious diseaseEurope PMCPMC
  2. Persistent Injection-Site Nodules After the Administration of Long-Acting Cabotegravir/Rilpivirine
    Eisuke Adachi, Aiko Okazaki, Chiharu Shimazu
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  3. Viral suppression among adolescents and young people on antiretroviral treatment in a rural setting in Kenya, 2022
    Moses Muriithi Njiru, Maurice Owiny, Bridget Wesonga +4
    Journal of Interventional Epidemiology and Public HealthPeer-reviewedCC BYFull textInfectious diseaseDOAJ
  4. The effect of antiretroviral therapy adherence on viral load suppression rate among people living with HIV in Ethiopia: A systematic review and meta-analysis
    Desalegn Dawit Assele, Yitayew Ewnetu Mohammed, Abera Gezume Ganta +2
    PLOS OnePeer-reviewedCC BY 4.0Full textImmunologyMicrobiologyPLOS
  5. Beyond Viral Suppression: Quality of Life Among People Living With HIV in Czechia
    M Pitoňák, L Csémy, A Kubátová +7
    The European Journal of Public HealthPeer-reviewedCC BY-NC 4.0Full textInfectious diseasePMCEurope PMC

Cite

BibTeXRIS
BibTeX
@article{gistand2026longacting,
  title = {{Long-Acting Lenacapavir and Cabotegravir and Viral Suppression Among People With HIV}},
  author = {Nathanael L. Gistand and Ishaan C. Mishra and Kyle Hunter and Megan J. Heise and Chesa Cox and Janet Grochowski and Francis Mayorga-Munoz and Jon Oskarsson and Mary Shiels and Matthew A. Spinelli and Monica Gandhi},
  journal = {JAMA Network Open},
  year = {2026},
  month = oct,
  doi = {10.1001/jamanetworkopen.2026.38182},
  url = {https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2854975},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Long-Acting Lenacapavir and Cabotegravir and Viral Suppression Among People With HIV
AU  - Nathanael L. Gistand
AU  - Ishaan C. Mishra
AU  - Kyle Hunter
AU  - Megan J. Heise
AU  - Chesa Cox
AU  - Janet Grochowski
AU  - Francis Mayorga-Munoz
AU  - Jon Oskarsson
AU  - Mary Shiels
AU  - Matthew A. Spinelli
AU  - Monica Gandhi
PY  - 2026
DA  - 2026/10/08
JO  - JAMA Network Open
DO  - 10.1001/jamanetworkopen.2026.38182
UR  - https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2854975
AB  - This case series examines viral suppression outcomes among patients with HIV with prior adherence challenges, treatment experience, and resistance initiating lenacapavir and cabotegravir.
SN  - 2574-3805
ER  -